Published in Lab Law Weekly, May 19th, 2006
As part of the exercise, Gen-Probe has purchased preferred stock convertible into approximately 19.5% of Qualigen's fully diluted common shares for approximately $7 million.
If development is successful, the new platform, known as a closed unit-dose assay (CUDA) system, would use Gen-Probe's NAT technologies to rapidly detect, at the point of sample collection, the presence of harmful microorganisms and genetic mutations. The platform could...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.